Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2012 - 2026)

Enanta Pharmaceuticals has reported Cash & Current Investments for 15 years, with the latest figure at $163.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 15.31% year-over-year to $163.8 million; the trailing twelve-month figure through Mar 2026 stood at $163.8 million (down 15.31% YoY), and the FY2025 full-year result was $188.9 million, down 23.9% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $163.8 million, down from $185.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $386.6 million in Q2 2023, with the low at $85.4 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $232.2 million across 5 years, with a median of $216.7 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Current Investments sank 65.74% — and 2024, when it surged 190.66%.
• Enanta Pharmaceuticals' Cash & Current Investments stood at $214.5 million in 2022, then soared by 57.2% to $337.2 million in 2023, then sank by 35.73% to $216.7 million in 2024, then slipped by 14.23% to $185.8 million in 2025, then fell by 11.88% to $163.8 million in 2026.
• The last three Cash & Current Investments figures came in at $163.8 million (Q1 2026), $185.8 million (Q4 2025), and $188.9 million (Q3 2025), per Business Quant data.